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BACKGROUND: Ten years ago, leaders in the field of toxicology called for a transformation of the discipline and a shift from primarily relying on tradi-
tional animal testing to incorporating advances in biotechnology and predictive methodologies into alternative testing strategies (ATS). Governmental
agencies and academic and industry partners initiated programs to support such a transformation, but a decade later, the outcomes of these efforts are
not well understood.
OBJECTIVES:We aimed to assess the use of ATS and the perceived barriers and drivers to their adoption by toxicologists and by others working in, or
closely linked with, the field of toxicology.
METHODS: We surveyed 1,381 toxicologists and experts in associated fields regarding the viability and use of ATS and the perceived barriers and
drivers of ATS for a range of applications. We performed ranking, hierarchical clustering, and correlation analyses of the survey data.
RESULTS: Many respondents indicated that they were already using ATS, or believed that ATS were already viable approaches, for toxicological
assessment of one or more end points in their primary area of interest or concern (26–86%, depending on the specific ATS/application pair).
However, the proportions of respondents reporting use of ATS in the previous 12 mo were smaller (4.5–41%). Concern about regulatory acceptance
was the most commonly cited factor inhibiting the adoption of ATS, and a variety of technical concerns were also cited as significant barriers to ATS
viability. The factors most often cited as playing a significant role (currently or in the future) in driving the adoption of ATS were the need for expe-
dited toxicology information, the need for reduced toxicity testing costs, demand by regulatory agencies, and ethical or moral concerns.
CONCLUSIONS: Our findings indicate that the transformation of the field of toxicology is partly implemented, but significant barriers to acceptance and
adoption remain. https://doi.org/10.1289/EHP1435
Introduction
Toxicological assessment is central to ensuring safety and protection
from potentially dangerous substances. Yet, there is limited toxico-
logical information available for thousands of chemicals currently
present in consumer products, industrial processes, food, and the
environment (Gomez 2013; Neltner et al. 2013; Stephenson
2009; Tice et al. 2013). Conventional testing relies mainly on
whole-animal studies—dosing animals, usually mammals, with a
compound and comparing health end points with a control group
(National Research Council 2007). However, this approach has
been criticized for being slow and expensive, for failing to evaluate
all critical end points and life stages (Tice et al. 2013), for inaccur-
ately predicting human health impacts because of species-specific
responses to compounds (Leist and Hartung 2013), and for heavy
animal use (Tice et al. 2013). These limitations have led the
National Academy of Sciences (NAS), as well as governmental
agencies, scientists, and stakeholders across the globe, to call for a
rethinking of chemical safety evaluation (Judson et al. 2009;
National Research Council 2007).
The demand for accurate and efficient toxicology testing, and
the advent of new techniques in molecular and computational biol-
ogy, spurred the development of alternative testing strategies
(ATS). These are primarily in vitro and in silico methodologies
that evaluate changes in biological processes at the molecular, cel-
lular, and tissue levels. For example, high-throughput screening
(HTS) approaches use advanced robotics and automation to test
hundreds to thousands of samples at a time (National Research
Council 2007). Read-across and quantitative structure–activity
relationship model (QSAR) approaches can be used to estimate
the toxicity of data-poor chemicals based on data from similar
chemicals (National Research Council 2007). Such a combination
of approaches has recently been evaluated and was deemed ac-
ceptable by the Endocrine Disruptor Screening Program of the
U.S. Environmental Protection Agency (EPA) as a valuable alter-
native to several Tier 1 assays for chemicals with estrogen activity
(Browne et al. 2015). However, the initial vision put forth in the
NAS report was also met with some reticence and pessimism with
regard to the challenges that would need to be overcome for its
implementation (Andersen and Krewski 2010). Furthermore, a
decade after the NAS acknowledged the transformational role
ATS could play in risk management, little is known about how
widespread the use of ATS is and what could be done to accelerate
its acceptance.
We addressed this gap by conducting a survey of scientists
and nonscientists whose training and/or occupation reside in, or
are closely linked with, the field of toxicology. The survey aimed
to answer three main questions: a) What is the current degree of
acceptance of ATS? b) What are the barriers to the widespread
adoption of ATS? c) What factors promote their adoption? We
developed the survey questions by drawing upon a literature
review and upon 19 semistructured interviews of experts from
industry, government, nongovernmental organizations, and aca-
demia in the United States and Europe. The online questionnaire,
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disseminated through toxicological professional societies and
trade groups, was completed by 1,381 respondents whose
responses provided information on their perceptions of the use
and utility of ATS for a range of applications and settings.
To our knowledge, this is the first comprehensive summary of
toxicologists’ opinions about the state and utility of alternative
toxicity testing since the NAS issued a 2007 report calling for a
paradigm shift in toxicology (National Research Council 2007).
We report survey findings regarding the nature and scope of ATS
use within private businesses and public agencies, and respond-
ents’ perceptions of the scientific and sociolegal barriers to and
drivers of broader adoption. We conclude with a discussion of
the likely impact of recent reforms of the federal Toxic
Substances Control Act on the adoption of ATS for regulatory
purposes.
Methods
Survey Design
Survey design began with semistructured interviews conducted
by phone with 19 toxicology experts between November 2013
and March 2014. Participants included toxicologists and other
experts working for state and national governments, various sec-
tors of industry, and nonprofit groups in the United States and
Europe. The interviews were conducted using a prepared set of
interview topics and themes, but leaving open the opportunity to
explore additional topics or information that arose during the
interview. Topics included the respondents’ overall knowledge of
alternative testing approaches; their use of these alternative test-
ing approaches; their perception of the viability, advantages, and
drawbacks of these alternative testing approaches; their views
regarding the use of data generated by alternative testing
approaches into risk assessment, management, and the regulatory
context; and their perception of the future of the field pertaining
to these alternative testing approaches.
The digitally recorded interviews were summarized by topic
area in a Microsoft Excel spreadsheet, and the results were used
to generate a draft version of the survey, along with information
from the literature and the experience of the project team. The
draft survey was piloted with three experts in toxicology testing
and regulation drawn from business, government, and academia.
Each pilot respondent completed the entire survey, providing
contemporaneous comments regarding the survey design, includ-
ing comments regarding structure, terminology, clarity, and
scope. The comments were recorded and reviewed by the project
team, and revisions to the survey were made where necessary to
address concerns reflected in the comments. A PDF version of
the final online survey can be accessed in the Supplemental
Material (“Survey and Answers”).
The survey primarily focused upon six types of ATS identi-
fied in the literature (Collins et al. 2008; Leung et al. 2008;
National Research Council 2007; Yang et al. 2009), which were
described in the survey as follows: mechanistically based in vitro
cell or biochemical assays, high-throughput in vitro cell or bio-
chemical assays, mechanistically based in vivo small-animal
assays (e.g., zebrafish or C. elegans), high-throughput in vivo
small-animal assays (e.g., zebrafish or C. elegans), QSARs, and
biomarkers. Because the survey was directed at toxicologists and
experts in related fields, no definitions of the ATS types were
included in the survey. For readers who may be unfamiliar with
one or more ATS types, descriptions of the ATS types derived
from the relevant literature are provided in the Supplemental
Material (see Table S1). Respondents were asked to assess the
current and future viability of each ATS type for seven specified
applications for one or more end points in their respective
primary areas of interest or concern: screening/prioritization for
further testing; screening/prioritization for other actions (e.g., risk
assessment, risk management); setting doses for in vivo testing;
weight of evidence in quantitative risk assessment (scoping to
determine the most sensitive end points); qualitative risk
assessment (e.g., control banding); quantitative risk assessment
[identifying the no observed adverse effects level (NOAEL) or
other levels]; comparative assessment of alternative chemicals/
products/processes (alternatives analysis). Again, because the
survey was directed at toxicologists and experts in related fields,
no definitions of the potential applications were included in the
survey (see Table S2 for descriptions of the applications). We
also queried respondents regarding specified sets of potential bar-
riers to and drivers of adoption of each of the six ATS types.
Additionally, the survey collected information regarding the
respondent’s gender, age, country of work, employer type, indus-
try sector, current position, and education (Table 1), which
Table 1. Demographic information of survey respondents.
Characteristic n (%)
Gender 1,310a
Female 481 (36.7)
Male 826 (63.0)
Other 3 (0.2)
Did not answer 71
Year of most recent degree 1,302
2010–present 166 (12.7)
2000–2009 329 (25.3)
1990–1999 350 (26.7)
1980–1989 291 (22.4)
1970–1979 129 (9.9)
Before 1970 37 (2.8)
Did not answer 79
Geographic region 1,324
Europe 201 (15.2)
North America 991 (74.8)
Other 132 (10.0)
Did not answer 57
Degrees heldb 1,319
Undergraduate 557 (42.2)
Masters 459 (34.8)
Doctorate 1,037 (78.6)
Medical 59 (4.5)
Law 5 (0.4)
Other 71 (5.4)
Did not answer 62
Employer 1,381
Academia/research institute 403 (29.2)
Large business 318 (23.0)
Small/medium business 89 (6.4)
National government 180 (13.0)
State/local government 53 (3.8)
Other 338 (24.5)
Did not answer 0
Sectorc 1,328
Pharmaceuticals only 271 (20.4)
Other 1,057 (79.6)
Did not answer 53
aIndicates the total number of responses to each demographic question.
bRespondents were asked, “In which of the following countries do you primarily work?”
Respondents could select more than one country. Respondents who only selected North
American countries were classified as “North America.” Respondents who selected any
European country were classified as “Europe.” Respondents who selected neither North
American nor European countries but did select other countries were classified as
“Other.”
cRespondents were asked to “identify what degree(s) you hold.” More than one degree
could be indicated. Percentages indicate the number of people who selected each degree
over the total number of people who responded to the question.
dRespondents were asked, “To which industry sectors, if any, does your work relate?”
Respondents could select more than one sector. Numbers and percentages reflect
respondents who only selected “pharmaceuticals.”
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allowed us to compare the sample frame with the Society of
Toxicology’s (SoT’s) demographics (see Table S3).
We conducted the survey between 26 September 2014 and
14 November 2014, with 95% of the responses received between
the start date and 30 October 2014. The responses (n=1,381) were
collected using the online survey application Qualtrics (https://
www.qualtrics.com/). The sampling frame consisted of members
of professional societies most closely associated with toxicology:
namely, SoT, the Society of Environmental Toxicology and
Chemistry (SETAC), the Center for Alternatives to Animal
Testing (CAAT), the American Society for Cellular and
Computational Toxicology (ASCCT), and AltTox. Currently
active toxicologists worldwide are likely to belong to at least one
of these organizations. SoT e-mailed one recruitment and one
follow-up e-mail to each of its members on our behalf, with an ap-
proximate response rate of 17% (n=936). An e-mail announce-
ment of the survey along with a single URL was distributed
through both SETAC and CAAT member communications, result-
ing in 462 additional responses. Separate links were also sent to
mailing lists of toxicologists at the U.S. EPA (n=7), ASCCT
(n=18), and AltTox (n=11), resulting in 36 additional
responses to the survey. The response rates for SETAC, CAAT,
U.S. EPA, ASCCT, and AltTox cannot be calculated given the
nature of the recruitment process and the fact that the member-
ship lists of these associations and organizations overlap.
Participants were given the option of providing their name and
e-mail address at the end of the survey if they were willing to be
contacted for follow-up questions; otherwise, their responses
were anonymous.
The survey was designed so that individual items may not
be relevant to all respondents. Consequently, the number of
responses to individual questions varied. All participants’ per-
sonal information was confidential, and survey administrators
and analysists were blinded to the identity of the respondents
as described in the Institutional Review Board (IRB) exemp-
tion granted by University of California, Los Angeles (UCLA)
(IRB No. 13-001339). The summary of the responses without
identifiers can be found in the Supplemental Material (see
“Survey and Responses”).
Statistical and Clustering Analyses
We examined respondents’ answers for four categories of ques-
tions: familiarity with ATS (question 12), current use and per-
ceived viability of each of six ATS approaches (questions 16–
21), perceived barriers to viability or adoption (questions 23 and
24), and current or future drivers of adoption by the respondent
or by their organization (question 25). We used a two-step analy-
sis to identify meaningful differences among groups of respond-
ents for each of those categories. In the first step, we clustered
individuals using hierarchical clustering, a statistical method that
aims to recursively partition a set of multivariate measurements
on the basis of a dissimilarity measure. The technique mines the
data to identify nested groups of respondents who provided
similar answers, resulting in an easily interpretable dendro-
gram configuration of the original data. To accomplish this
aim, we generated groups of subjects using the agglomerative
version of Ward’s complete linkage minimum variance algorithm
with Manhattan distance matrices, and our analysis was imple-
mented using the R function “hclust” (R Project for Statistical
Computing). In all applications, the “other” category was excluded
owing to a high prevalence of nonresponse. In all other categories,
nonresponse was only excluded in the computation of pairwise dis-
tances. For a conservative interpretation of the dissimilarities among
the respondents, we broke the respondents into two major clusters
for each of the categories of questions, which separated the
respondents into two easily interpretable categories. For example,
cluster analysis of the viability of mechanistically based in vitro
assays generated two clusters of respondents, those perceiving high
viability and those perceiving low viability. A detailed example of
how hierarchical clustering identifies latent classes of survey
respondents is illustrated for overall viability in Figure S1.
In the second analytical stage, we associated cluster mem-
bership with several of the respondents’ demographic charac-
teristics using a logistic regression model: year of terminal
degree (modeled as a continuous variable), employer type
(national government, state government, large business, small/
medium business, academia, and other), geographic associa-
tion (Europe, North America, and other), gender (M, F), and
sector (selected Pharma as only choice vs. did not select it). In
all of these analyses, we used males, North American, employ-
ment in a National Government as the baseline/reference
categories. The logistic regression model was assessed for
adequacy, comparing its classification results with random
forests (RF). Specifically, we compared cross-validation esti-
mates (10CV) of classification accuracy for both RF and logis-
tic regression. For all models, logistic regression models are at
most 5% less accurate than the RF estimate (Liaw and Wiener
2002). The data were processed for analysis in three steps:
cleaning up of the data, analysis, and report generation. In our
assessment of statistical significance, we controlled type I
errors (a) at or below 5%. Links to the complete data set, data
cleaning routing, the data analysis routines, and the report-
generating codes are available in the Supplemental Material
(see “Data and Code”).
Finally, the analysis of perception of viability by familiarity
with ATS (see Table S4) was performed by tabulating the percent-
age of survey respondents, classified by hierarchical clustering as
perceiving specific ATS strategies as being currently viable, by
degree of familiarity with specific ATS strategies. p-Values are
based on Chi-squared tests of independence. Controlling type I
errors at 5%, a p-value <0:05 identified a significant association
between perceived viability and familiarity categories. The analysis
of respondents’ characteristics with regard to familiarity (see Table
S5) was performed by categorizing familiarity into four classes:
namely, unfamiliar (unfamiliar with all listed technologies), some-
what familiar (somewhat familiar with fewer than half of the listed
technologies), familiar (somewhat or very familiar with more than
half, but not all, of the listed technologies), and very familiar (some-
what or very familiar with all listed technologies). The data were
then described as marginal associations between familiarity and
gender, degree year, employer, region, and pharma. The reported p-
values refer to Chi-squared tests of independence for categorical
predictors and to analysis of variance (ANOVA) F-tests for continu-
ous predictors (degree year).
Results
The survey respondents varied in age, professional background,
and geographic location. The majority of respondents were mem-
bers of SoT (68% of total respondents), our primary survey dis-
semination channel, and from the United States (73%). Nearly a
quarter of the respondents (23%) were from European Union coun-
tries. Further demographics characterization is found in Table 1.
To ascertain the representativeness of the respondent population,
we compared the demographics of the SoT membership at the
time of the survey with that of our respondent population. The
sample demographics aligned closely with the SoT demographics
with only three minor differences: the study sample population
was skewed toward people who obtained their last degree more
recently than the full SoT membership; government respondents
were over-represented (17% from the sample vs. 13% from SoT);
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and industry was under-represented (30% from the sample vs. 36%
from SoT) (see Table S3).
Use and Viability of Alternative Testing Strategies
Many respondents already perceive ATS as viable for a variety
of applications; that is, respondents either use ATS for a relevant
application or believe that it can be used currently for that appli-
cation. However, perception of viability varied considerably by
the intended use of the ATS (Table 2). For example, ATS for
screening or prioritizing chemicals for further testing had the
widest acceptance; depending upon the particular ATS approach,
70.1% to 86.4% of respondents viewed ATS to be currently ac-
ceptable. Acceptance of using ATS for establishing levels at
which toxic effects may occur (i.e., NOAELs) in quantitative risk
assessment (QRA) varied by ATS approach. Acceptance rates
were highest for QSARs (42.8%) and biomarkers (53.5%) and
lowest for HTS in vitro technologies (25.5%). Similarly, a major-
ity of respondents (69.2–53.2% depending upon the ATS
approach) considered ATS to be viable for the comparative
assessment of alternative chemicals.
The apparent support for current viability was tempered by
other survey results. Particularly with respect to its application
to QRA, notable numbers of respondents perceived most ATS
approaches as neither currently viable nor viable in the foresee-
able future (Table 3). For example, 25.7% of respondents
viewed QSARs as unfeasible for QRA; more than a third held
the same view of in vitro HTS. The biomarkers category was
the exception, with just 14.7% of respondents being skeptical.
Moreover, there was a gap between acceptance and actual use.
Although many respondents judged these technologies to be
currently viable for a variety of applications, fewer respondents
reported using the technologies for those applications. In terms
of current use, screening for further testing using mechanistic in
vitro approaches was most common (41.1%), whereas employ-
ing HTS in vivo for qualitative risk assessment was least com-
mon (4.5%) (Table 2). There is some indication that part of this
difference between perceived viability and actual use may be
related to regulatory constraints; as we discuss below, concern
about regulatory acceptance is one of the leading barriers to
adoption. However, a variety of other factors may also affect
the respondent’s use of a given method, including whether the
particular ATS/application is relevant to end points in their pri-
mary area of interest or concern and the scope of the respond-
ent’s job responsibilities.
Hierarchical clustering generated two groups of respondents
based on survey questions about the perceived viability of ATS
methods in a broad range of technologies and applications (Q14
Table 2. Use and viability: numbers (%) of participants who indicated that an alternative testing strategy technology is a viable approach for a toxicological
assessment (application) of one or more end points in their primary area of interest or concern.
Application
ATS Technologya n (%)
Mechanistic in vitro HTS in vitro Mechanistic in vivo HTS in vivo QSARs Biomarkers
Screening/prioritization for further testing 884b 851 790 738 942 845
Current userc 363 (41.1) 242 (28.4) 128 (16.2) 90 (12.2) 334 (35.5) 298 (35.3)
Currently viabled 379 (42.9) 452 (53.1) 458 (58.0) 427 (57.9) 480 (51.0) 399 (47.2)
Currently acceptablee 712 (83.9) 694 (81.6) 586 (74.2) 517 (70.1) 814 (86.4) 697 (82.5)
Screening/prioritization for other actions 859 827 773 720 911 846
Current user 273 (31.8) 156 (18.9) 98 (12.7) 70 (9.7) 309 (33.9) 264 (31.2)
Currently viable 343 (39.9) 404 (48.9) 400 (51.7) 356 (49.4) 389 (42.7) 387 (45.7)
Currently acceptable 616 (71.7) 560 (67.7) 498 (64.4) 426 (59.2) 698 (76.6) 651 (77.0)
Qualitative risk assessment 721 694 656 601 749 712
Current user 137 (19.0) 59 (8.5) 52 (7.9) 27 (4.5) 152 (20.3) 154 (21.6)
Currently viable 266 (36.9) 255 (36.7) 285 (43.4) 232 (38.6) 317 (42.3) 323 (45.4)
Currently acceptable 403 (55.9) 314 (45.2) 337 (51.4) 259 (43.1) 469 (62.6) 477 (67.0)
Setting doses for in vivo testing 824 764 729 693 842 781
Current user 145 (17.6) 70 (9.2) 76 (10.4) 49 (7.1) 137 (16.3) 195 (25.0)
Currently viable 265 (32.2) 212 (27.7) 254 (34.8) 214 (30.9) 306 (36.3) 304 (38.9)
Currently acceptable 410 (49.8) 282 (36.9) 330 (45.3) 263 (38.0) 443 (52.6) 499 (63.9)
Weight of evidence in quantitative risk assessment 828 783 745 689 874 799
Current user 187 (22.6) 80 (10.2) 78 (10.5) 41 (6.0) 229 (26.2) 209 (26.2)
Currently viable 300 (36.2) 289 (36.9) 310 (41.6) 242 (35.1) 336 (38.4) 341 (42.7)
Currently acceptable 487 (58.8) 369 (47.1) 388 (52.1) 283 (41.1) 565 (64.6) 550 (68.8)
Setting NOAEL or other levels in quantitative
risk assessment
799 758 743 684 873 774
Current user 100 (12.5) 44 (5.8) 66 (8.9) 39 (5.7) 176 (20.2) 164 (21.2)
Currently viable 162 (20.3) 149 (19.7) 179 (24.1) 145 (21.2) 198 (22.7) 250 (32.3)
Currently acceptable 262 (32.8) 193 (25.5) 245 (33.0) 184 (26.9) 374 (42.8) 414 (53.5)
Comparative assessment of alternatives 798 764 725 671 857 762
Current user 191 (23.9) 97 (12.7) 76 (10.5) 54 (8.0) 205 (23.9) 171 (22.4)
Currently viable 335 (42.0) 346 (45.3) 344 (47.4) 303 (45.2) 388 (45.3) 351 (46.1)
Currently acceptable 526 (65.9) 443 (58.0) 420 (57.9) 357 (53.2) 593 (69.3) 522 (68.5)
Note: ATS, alternative testing strategies; HTS, high-throughput screening; NOAEL, no observable adverse effects level; QSAR, quantitative structure–activity relationship. For each
technology, respondents were asked, “To what extent do you believe that the use of [the technology] is a viable approach for the following aspects of toxicological assessment for one
or more end points in your primary area of interest or concern?” For each application, respondents were given the following choices: “I have used it for this purpose in the last 12
months,” “Is a viable use, but I have not used it for this purpose in the last 12 months,” “Not currently viable, but may be viable within 1–5 years,” “Not currently viable, but may be
viable within 5-10 years,” “Not a viable use now or in the foreseeable future,” and “Do not know/not sure.” Percentages for each technology/application pair are based on the number
of respondents who answered the question, excluding “Do not know/not sure” responses.
aSurvey questions used the following terms to describe the six ATS technologies: Mechanistic in vitro, mechanistically based in vitro cell or biochemical assays; HTS in vitro, high-
throughput screening in vitro cell or biochemical assays; mechanistic in vivo, mechanistically-based in vivo cell or small-animal assays (e.g., zebrafish or C. elegans); HTS in vitro,
high-throughput screening in vivo small-animal assays (e.g., zebrafish or C. elegans); QSARs, quantitative structure activity relationship models; biomarkers, biomarkers].
bIndicates the total number of responses for each technology/application combination.
cCurrent users indicated, “I have used it for this purpose in the last 12 months.”
d“Currently viable” means respondents indicated, “Is a viable use, but I have not used it for this purpose in the last 12 months.”
eCurrently acceptable is the sum of “Current user” and “Currently viable” for each technology/application combination.
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to Q19) (see Figure S1). A post hoc examination of the clustering
results identified one group of respondents perceiving most appli-
cations of ATS as being highly viable in the short term (90% of
respondents see most applications as potentially viable currently
or within the next 5 y), and the comparison group with a more
critical attitude towards the short-term viability (50% of respond-
ents identifying only between 45% and 84% of ATS applications
as viable currently or within the next 5 y). Logistic regression
analyses identified that degree year was modestly positively con-
sistently correlated with perceived viability of technologies [OR
for a 10-y increase = 1:03 (95% CI: 1.02, 1.05); p=0:001] (Table
4). There was no statistical difference between the views of
Europeans and North Americans. Compared with respondents
working in all other sectors combined, those working in the phar-
maceutical industry were less likely to view ATS as viable,
although the difference was not significant [OR=0:92 (95% CI:
0.65, 1.30); p=0:642].
Finally, we investigated whether familiarity was a potential
factor behind the perception of viability. The more familiar a re-
spondent was with a given technology, the more likely the re-
spondent was to perceive it as currently viable for at least one use
(see Table S4). This factor appears to be particularly important for
recent graduates, for people outside of the United States, and for
employees of small/medium businesses who are all on balance
less familiar with alternative testing approaches (see Table S5).
Barriers to Adoption of Alternative Testing Strategies
The survey included two questions related to barriers to ATS. The
first question asked participants to indicate, for each of the alterna-
tive approaches that they believed was not currently viable, the
factors they saw as significant barriers to viability. Possible
responses to this question included 11 scientific or technical fac-
tors that might be perceived as barriers (Figure 1A). The second
question asked participants to indicate which of 13 possible social/
legal/institutional barriers they thought played a significant role in
inhibiting adoption of the six ATS by the respondent or by others
in their organization (Figure 1B). By total number of responses
across the six ATS, scientific/technical barriers accounted for 4 of
the 5 most frequent responses to the two questions combined.
These technical barriers included concerns with regard to the inter-
pretation and extrapolation of the data, failure to capture the inte-
grated whole-animal system, the difficulty in developing dose–
response relationships, and concerns with the accuracy in terms of
false positives and false negatives (Figure 1A). The rank order of
the barriers was generally consistent across the approaches, with
two exceptions. The failure to capture the integrated whole-
animal system was the leading barrier for three approaches:
mechanistically based in vitro assays, HTS in vitro assays, and
QSARs. This barrier dropped to eighth for biomarkers and to
ninth for mechanistically based in vivo small animal assays and
HTS in vivo small animal assays. In addition, difficulties in
management/synthesis of large amounts of data were a leading
barrier for high-throughput testing approaches, but not for the
other testing approaches. Notably, the two least commonly indi-
cated scientific/technical barriers were “existing testing
approaches are adequate” and “not scientifically sound.”
In the next question, we inquired about social/legal/institu-
tional barriers that may inhibit ATS adoption by the respondents
or by their organization. By a wide margin, respondents indicated
“concern about regulatory acceptance” as the most common fac-
tor inhibiting the adoption of ATS (2,192 positive responses), fol-
lowed by “lack of scientific validation” (1,571 responses) (Figure
1B). Concerns regarding the current validity and the validation
process for ATS methods were the next-most-prominent per-
ceived nontechnical barriers, including the complexity and pace
of validation as well as the availability of validated ATS meth-
ods. Validation is the process by which “the reliability and rele-
vance of a new method is established for a specific purpose”
(OECD 2005). Another significant social/legal/institutional bar-
rier is general resistance to change, which is addressed in more
detail in the discussion below.
Hierarchical clustering generated two groups of respondents
based on survey questions about factors that they perceived as
significant barriers to the viability of one or more ATS (Q21) and
factors that they believed play a significant role in inhibiting the
adoption of ATS (Q22), with one group identifying more barriers
(50% of respondents identifying between 39 and 67 barriers) and
the comparison group identifying fewer barriers (50% of respond-
ents identifying between 12 and 27 barriers). In our analysis, we
Table 3. Nonviable alternative testing strategies: numbers (%) of respondents who indicated that an ATS technology is not a viable approach for a toxicological
assessment (application) of one or more end points in their primary area of interest or concern.
Application Mechanistic in vitro HTS in vitro Mechanistic in vivo HTS in vivo QSARs Biomarkers
Screening/prioritization for further testing 26/884 (2.9) 38/851 (4.5) 56/790 (7.1) 70/738 (9.5) 26/942 (2.8) 33/845 (3.9)
Screening/prioritization for other actions 51/859 (5.9) 77/827 (9.3) 78/773 (10.1) 90/720 (12.5) 43/911 (4.7) 42/846 (5.0)
Qualitative risk assessment 83/721 (11.5) 114/694 (16.4) 113/656 (17.2) 120/601 (20.0) 60/749 (8.0) 61/712 (8.6)
Setting doses for in vivo testing 134/824 (16.3) 191/764 (25.0) 167/729 (22.9) 187/693 (27.0) 146/842 (17.3) 78/781 (10.0)
Weight of evidence in quantitative risk
assessment
94/828 (11.4) 127/783 (16.2) 127/745 (17.0) 156/689 (22.6) 75/874 (8.6) 65/799 (8.1)
Quantitative risk assessment (identifying
NOAEL or other levels)
213/799 (26.7) 264/758 (34.8) 230/743 (31.0) 243/684 (35.5) 224/873 (25.7) 114/774 (14.7)
Comparative assessment of alternatives 59/798 (7.4) 85/764 (11.1) 101/725 (13.9) 106/671 (15.8) 60/857 (7.0) 54/762% (7.1)
Note: ATS, alternative testing strategies; HTS, high-throughput screening; NOAEL, no observable adverse effects level; QSAR, quantitative structure–activity relationship. Survey
questions were the same as those in Table 2. Percentages for each technology/application pair are based on the number of respondents who selected “Not a viable use now or in the
foreseeable future” divided by the total number of respondents for that technology/use combination excluding “do not know/not sure” responses.
Table 4. Logistic regression: Overall viability.
Characteristic OR (95% CI)
Natural log
OR SE p-Value
Gender (F)a 1.07 (0.82, 1.39) 0.07 0.14 0.614
Degree year/10 y 1.03 (1.02, 1.05) 0.03 0.01 0.001
Region (Europe) 1.11 (0.78, 1.57) 0.10 0.18 0.564
Region (other) 1.01 (0.66, 1.53) 0.01 0.22 0.975
Employer (small/medium
business)
1.58 (0.85, 2.94) 0.46 0.32 0.152
Employer (large business) 1.35 (0.84, 2.18) 0.30 0.24 0.215
Employer (state government) 1.91 (0.90, 4.03) 0.65 0.38 0.091
Employer (academia) 1.66 (1.04, 2.65) 0.51 0.24 0.033
Employer (other) 1.74 (1.11, 2.74) 0.56 0.23 0.016
Sector (Pharma) 0.92 (0.65, 1.30) −0:08 0.18 0.642
Note: ATS perceived as viable explained by respondents’ characteristics compared with
a reference group of U.S. males working for a national government organization and not
associated with the pharmaceutical industry. ATS, atlernative testing strategies; CI, con-
fidence interval; OR, odds ratio; SE, standard error.
aThree subjects classified as “Other” are not included in this analysis.
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disregarded subjects who did not respond to at least one question
in Q21 and Q22. Logistic regression model results indicated that
respondents who worked primarily in Europe were less likely to
perceive a high number of barriers to adoption of ATS compared
with North Americans [OR=0:56 (95% CI: 0.35, 0.90);
p=0:017]. Respondents working for all other employer catego-
ries were significantly less likely than those working for a
national government to indicate barriers (Table 5). Women were
significantly less likely than men to indicate barriers, and a 10-y
increment in degree year was also negatively associated with bar-
riers. Compared with other sectors, respondents employed by the
pharmaceutical industry also indicated fewer barriers, although
the association was not significant.
Drivers of Adoption of Alternative Testing Strategies
We asked the participants to identify which of the several factors,
if any, play or will play a significant role in driving the adoption
of ATS by them or by their organization. The leading perceived
drivers of adoption, for the most part, reflected the normative and
methodological factors that have driven the 3Rs concept (replace-
ment, reduction, and refinement) for decades as well as the 2007
Figure 1. Social and institutional barriers. (A) Respondents were asked to identify, for each alternative approach they believe is not currently viable, which fac-
tors they see as significant barriers to viability (Question 21). (B) Additionally, the respondents were asked to identify which factors, if any, they think play a
significant role in inhibiting the adoption of the listed alternative approaches by them or by others in their organization (Question 22). For both panels, the y-
axis represents the total number of responses collected and is further divided by category of alternative technology. Respondents were able to select as many
perceived barriers as they wished for each technology. “Other” responses were not included.
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NAS report (National Research Council 2007), including the need
for expedited toxicity information, reducing testing costs, and ethi-
cal concerns regarding animal impacts (Figure 2). The third most
cited potential driver—demand by regulatory agencies—focuses
instead upon the institutional context. The survey data were also
noteworthy in what respondents did not commonly identify as sig-
nificant drivers. For example, the need to compete with others in
the industry and demand by the general public, by customers, or
by NGOs represented the bottom four answers by overall ranking.
The rank order of drivers changed little when examining the
six different types of ATS; it also varied little when compared by
age (i.e., degree year), by gender, by European versus North
American location, or by employer. Hierarchical clustering gen-
erated two groups of respondents based on survey questions
about factors potentially playing a significant role in driving the
adoption of ATS (Q13), with one group identifying only a limited
number of drivers (50% of responders identified between 6 and
18 drivers), and the other group identifying a significantly large
number (50% of responders identified between 21 and 36 driv-
ers). As before, in our analysis, we disregarded subjects who did
not respond to at least one question in Q13. A logistic regression
analysis confirmed that no significant differences were observed
between groups aside from non-North American/European
respondents and from small/medium business employees, who
overall perceived fewer drivers to the field when compared with
the reference group (Table 6).
Discussion
In this study, we aimed to assess the dynamics and tensions that
have animated the evolution of the field of toxicology over the
last 10 y. Findings from our survey of 1,381 toxicologists and
people working in related areas suggest that current use and per-
ceptions regarding the current viability of novel testing methods
(which we refer to, in combination, as “acceptance” of ATS) var-
ied depending on the type of testing approach and depending on
the particular application. Our study also revealed that the per-
ceived barriers to and drivers of the adoption of alternative meth-
ods differed by geographical location and by type of employer.
By contrast, the top drivers, that is to say, expedited information,
reduced costs, and regulatory demand, were more commonly
shared among respondents. Taken together, these results shed
Table 5. Logistic regression: Barriers.
Characteristic OR (95% CI)
Natural
log SE p-Value
Gender (F)a 0.71 (0.52, 0.97) −0:34 0.16 0.030
Degree year/10 y 0.97 (0.96, 0.99) −0:03 0.01 0.001
Region (Europe) 0.56 (0.35, 0.90) −0:58 0.24 0.017
Region (other) 0.89 (0.54, 1.47) −0:12 0.26 0.635
Employer (small/medium
business)
0.36 (0.18, 0.70) −1:03 0.34 0.003
Employer (large business) 0.60 (0.39, 0.92) −0:51 0.22 0.021
Employer (state government) 0.28 (0.11, 0.72) −1:26 0.48 0.008
Employer (academia) 0.31 (0.20, 0.49) −1:17 0.24 0.001
Employer (other) 0.38 (0.25, 0.59) −0:96 0.22 0.001
Sector (Pharma) 0.80 (0.55, 1.15) −0:23 0.19 0.224
Note: Perceived barriers explained by respondents’ characteristics compared with a ref-
erence group of U.S. males working for a national government organization and not
associated with the pharmaceutical industry. CI, confidence interval; OR, odds ratio;
SE, standard error.
aThree subjects classified as “Other” are not included in this analysis.
Figure 2. Drivers of adoption of alternative technologies. Respondents were asked to identify which factors, if any, they think play a significant role in driving
the adoption of the listed alternative approaches by them or by others in their organization (Question 23). The list of drivers was further divided according to
each category of alternative technology. The y-axis represents the total number of responses collected. Respondents were able to select as many perceived driv-
ers as they wished for each technology. “Other” responses were not included.
Table 6. Logistic regression: Drivers.
Characteristic OR (95% CI) Natural log SE p-Value
Gender (F)a 0.75 (0.54, 1.04) −0:29 0.17 0.085
Degree year/10 y 0.99 (0.97, 1.00) −0:01 0.01 0.084
Region (Europe) 0.64 (0.40, 1.01) −0:45 0.23 0.055
Region (other) 0.45 (0.26, 0.79) −0:79 0.28 0.005
Employer (small/medium
business)
0.42 (0.20, 0.87) −0:87 0.37 0.019
Employer (large business) 0.97 (0.60, 1.58) −0:03 0.25 0.909
Employer (state government) 0.48 (0.19, 1.21) −0:74 0.48 0.120
Employer (academia) 0.71 (0.43, 1.18) −0:34 0.26 0.187
Employer (other) 0.82 (0.51, 1.32) −0:20 0.25 0.406
Sector (Pharma) 1.19 (0.80, 1.77) 0.18 0.20 0.385
Note: Perceived drivers explained by respondents’ characteristics compared with a refer-
ence group of U.S. males working for a national government organization and not asso-
ciated with the pharmaceutical industry. CI, confidence interval; OR, odds ratio; SE,
standard error.
aThree subjects classified as “Other” are not included in this analysis.
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light on differences among those working in the field regarding
the application of ATS and provide some guidance on what is—
and what is not—needed to drive integration.
Our survey and analysis had several limitations that should be
considered when interpreting our findings. First, although the par-
ticipants appeared to be representative of SoT members as a
whole, our study population was a sample of people who volun-
tarily responded to survey invitations sent primarily to members
of professional societies; therefore, they may not be representative
of all scientists and nonscientists who are trained in, working in,
or closely linked to the field of toxicology. In addition, the major-
ity of the participants were from the United States, and nearly half
were working in the pharmaceutical sector, whereas the numbers
of participants from other countries and from some industry sec-
tors and employer types were limited. Numbers of responses var-
ied among the different questions, and it is not possible to
determine the underlying causes of missing data in all cases.
The findings with regard to the wide acceptance of ATS in
the survey for screening and prioritization is consistent with those
of the NAS report and with much of the academic literature
(Hartung 2009; National Research Council 2007; Thomas et al.
2013). The NAS report envisioned full integration of ATS into
toxicology as a stepwise, decades-long process, with early appli-
cations of ATS for screening and prioritization being followed by
use in risk assessment (Firestone et al. 2010; National Research
Council 2007). Much of the relevant literature also identifies
screening and prioritization as appropriate current applications
for ATS (Cote et al. 2016; Judson et al. 2010). Views on a more
limited role for most ATS methods in QRA in the near term have
been expressed (Cote et al. 2016; Crump et al. 2010; Wignall
et al. 2014), although some reports have also been more optimis-
tic (Adeleye et al. 2015; Judson et al. 2011). The survey results
suggest a divergence from this vision, particularly with respect to
the use of ATS in QRA. Depending upon the ATS approach,
25.5% to 53.5% of respondents already view ATS as currently
viable for identifying NOAELs and similar levels in QRA, and
5.7–21.2% of respondents already use ATS for this purpose
(Table 2). In contrast, and with one exception, a number of
respondents (14.7–35.5%) indicated that ATS has no such role to
play in the foreseeable future (Table 3). Although further inquiry
will be necessary to dissect the root of the differences in percep-
tion, the survey data identify potential factors. As discussed
above, one factor is familiarity: the more familiar a respondent
was with a given technology, the more likely the respondent was
to perceive it as currently viable for at least one use (see Tables
S4, S5). This finding suggests that an emphasis on education and
training may be helpful in enhancing the acceptance and imple-
mentation of ATS.
The majority of respondents also indicated that they currently
used or that they viewed ATS methods as currently viable for
comparative assessments of alternative chemicals, products, or
processes (53–69%, depending on the ATS). Alternatives analysis
or alternatives assessment is an emerging method used in regula-
tory and private contexts to identify and select safer alternatives
for chemicals of concern in consumer products and industrial proc-
esses (National Research Council 2014). Regulatory programs in
California and in the European Union mandate that manufacturers
or other responsible parties perform alternatives analysis for speci-
fied uses of chemicals of particular concern (DTSC 2013;
European Parliament and Council 2006). Both programs explicitly
allow for the use of ATS in comparing the risks of the incumbent
chemical with potential alternatives (ECHA 2011; OEHHA 2012).
The perceived viability of ATS for these uses may at least partly
reflect the comparative orientation of alternatives analysis; finely
grained, quantitative results specifying a single acceptable
exposure level are less critical in this context than in quantitative
risk assessment (Hjorth et al 2017; Niska et al. 2008).
Regarding barriers and drivers of adoption, one striking para-
dox emerges. Concern about regulatory acceptance was the most
commonly selected factor that “plays a significant role in inhibi-
ting the adoption of ATS” by respondents or by others in their
organizations, but demand by regulatory agencies was also fre-
quently cited as a factor that “plays (or will play) a significant role
in driving the adoption” of ATS by respondents or by other people
in their organizations. Cross-tabulations of the questions about bar-
riers and drivers indicated that that more than half of the respond-
ents who cited regulatory acceptance as a current barrier also cited
regulatory demand as a current or future driver of ATS adoption
(data not shown). This paradox may reflect the nature of the regula-
tory enterprise itself, in which regulatory agencies must balance the
need for cost-effective, timely toxicity information against the
understandable importance placed by them upon legitimacy, consis-
tency in regulatory action, and cautious appraisal and considered
adoption of new technologies in order to avoid the perception of
rash agency action. We believe that the use of ATS data for regula-
tory purposes will become increasingly common over time.
General resistance to change was the sixth most commonly
cited factor (out of 13) that “plays a significant role in inhibiting
the adoption” of ATS. Once established, technical capacities and
routine practices of the sort seen in conventional regulatory toxi-
cology are difficult to change because of the resources and incen-
tive structures that develop over time to support them (Malloy
2011). Of course, business firms and regulatory agencies are not
monolithic; in some cases, specific individuals and groups within
the organization may be more focused upon generating and
deploying new methods and practices. For example, innovation is
central to the mission of the Office of Research and Development
within the U.S. EPA; accordingly, this office has been spearhead-
ing advances in ATS at the U.S. EPA (Judson et al. 2010).
However, real change within regulatory programs may necessi-
tate mandating the use of ATS approaches where scientifically
appropriate. Similarly, changes to conventional validation proc-
esses will likely be necessary to accelerate the availability and
credibility of emerging ATS methods.
Finally, it should be noted that both barriers and drivers are
dynamic and interactive. For example, in line with the perceived im-
portance of demands by regulatory agencies as a driver to the adop-
tion of ATS, recent changes in U.S. chemicals law could have a
significant impact. In June 2016, the Frank R. Lautenberg Chemical
Safety for the 21st Century Act (the “Act”) was enacted, substan-
tially reforming the federal Toxic Substances Control Act (TSCA)
(U.S. Congress 2016). Among other things, the Act amends the
TSCA to include three provisions focused upon the reduction of
testing on vertebrates. The first provision creates a “soft” mandate
for the use of ATS in screening. The provision requires that before
testing on vertebrate animals, the U.S. EPA must consider reason-
ably available information such as computational toxicology and
bioinformatics, HTS methods, and the prediction models of those
methods to the extent that they are practicable and scientifically
justified. The second provision directs the U.S. EPA to encourage
and facilitate the use of scientifically valid alternative test methods
and chemical grouping approaches to reduce or replace testing on
vertebrate animals. The third provision requires the U.S. EPA to
develop a strategic plan by June 2018 to promote development
and implementation of alternative test strategies, including compu-
tational toxicology and bioinformatics, HTS screening, testing of
categories of chemicals, in vitro studies, and systems biology. On
their face, the three provisions strongly encourage the develop-
ment and use of ATS within the TSCA program, yet they do little
to address the fifth- and sixth-ranked social/legal/institutional
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barriers, general resistance to change and complexity/slowness
of the Interagency Coordinating Committee on the Validation
of Alternative Methods/European Centre for the Validation of
Alternative Methods (ICCVAM/ECVAM) validation processes,
respectively. Regarding resistance to change, which may be pres-
ent within regulated entities and within the U.S. EPA as well, the
provisions permit and encourage the use of ATS where scientifi-
cally appropriate, but, with very limited exceptions, they do not
mandate ATS use in such circumstances. Additionally, the statute
requires no efforts by relevant agencies to streamline the
ICCVAM validation process.
Other provisions of the TSCA reform legislation may create
regulatory demand sufficient to accelerate the adoption of ATS
approaches in regulatory decision making. Under the statute, the
U.S. EPA faces challenging deadlines for screening and prioritiza-
tion of existing chemicals in commerce and for risk evaluation of
those chemicals ultimately prioritized for review and action. As a
matter of necessity, regulated entities and the agency itself may
come to increasingly rely upon ATS approaches to meet their new
obligations. Even without explicit mandates to adopt appropriate
ATS methods, this regulatory demand may indirectly overcome
inertia and other institutional constraints on the adoption of ATS.
Conclusion
The present survey was conducted to determine the extent of cur-
rent ATS use and to gather information about barriers and drivers
that might help ATS proponents increase its acceptance. Overall,
it appears that toxicology as a field has followed the path
described by the NAS report in 2007, with initial use of ATS for
screening and prioritization, eventually followed by use for risk
assessment (National Research Council 2007). However, the
respondents differed with regard to whether ATS was currently
viable, versus unlikely to be viable for the foreseeable future, to
assess end points in their primary area of interest or concern, par-
ticularly with respect to QRA. The perceived obstacles to further
development and adoption were largely common to all forms of
ATS, as were the factors that participants cited as current or
future drivers. In addition to technological and validation issues,
institutional factors relating to regulatory acceptance, resistance
to change, and constraints associated with conventional valida-
tion processes are viewed as significant barriers. Respondents
indicated that along with demand by regulatory agencies, the
need for expedited toxicity information, the need for reduced tox-
icity testing costs, and ethical and moral concerns regarding the
use of animals in testing were the four most commonly cited fac-
tors that played or will play a significant role in their own or in
their organization’s adoption of ATS, whereas the need to com-
pete with others in their industry and demand by customers,
NGOs, and the general public were the four factors least likely to
be cited as current or future drivers of ATS adoption. In conclu-
sion, taking into account the aforementioned survey limitations,
the survey findings provide important information that may be
used to inform efforts to promote the use and acceptance of ATS.
Based on our interpretation of the findings, we recommend that
in addition to continued scientific research and development, a
two-pronged intervention be considered to move the field of toxi-
cology further into the 21st century; this intervention would con-
sist of bottom-up coordinated efforts from stakeholders to
encourage adoption of ATS approaches coupled with top-down
legal and institutional changes focused on expediting regulatory
acceptance of a diverse range of technologies. For example,
increased efforts by interested nongovernmental organizations to
encourage the development and adoption of ATS by regulators
and businesses and to educate consumers and the general public
about the potential of ATS could enhance adoption. Similarly,
sustained efforts by change agents within federal institutions such
as the Interagency Center for the Evaluation of Alternative
Toxicological Methods could reduce barriers to validation, partic-
ularly in light of recent changes to the TSCA (Casey 2016).
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